ライフサイエンスコーパス: multicentre trial

1 ve, randomized, blinded, placebo controlled, multicentre trial.

2 phase III, double-blind, placebo-controlled, multicentre trial.

3 randomised, placebo-controlled, double-blind multicentre trial.

4 lic hepatitis pending the results from large multicentre trials.

5 genesis and are currently being evaluated in multicentre trials.

6 d, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland, Germany, the Net

7 rdised care can also facilitate planning for multicentre trials and help with the identification of a

8 Multicentre trials are needed to show whether vitamin su

9 More large, well-designed multicentre trials are needed to support the conclusion

10 uble-blind, double-dummy, active-controlled, multicentre trial at 117 academic and community neurolog

11 PN-RC 111-a single-arm, open-label, phase 2, multicentre trial at 17 hospitals and cancer centres in

12 PN-RC 112-a randomised, open-label, phase 3, multicentre trial at 25 hospitals and cancer centres in

13 We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five countries and en

14 andomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China.

15 randomised double-blind, placebo-controlled, multicentre trial at three sites in Delhi (urban), Pune

16 Results from this multicentre trial build on findings from the phase 1 STA

17 e aimed to facilitate the use of NfL in gFTD multicentre trials by testing its (1) reliability across

18 , double-blind, phase 3, placebo-controlled, multicentre trial compared once-daily subcutaneous admin

19 l was a prospective, open-label, single-arm, multicentre trial conducted at 157 SHS across England be

20 Multicentre trials contradicted the benefits of tight co

21 , randomised, open-label, active-controlled, multicentre trial done at 159 sites in 34 countries outs

22 scalation (part 1), dose-expansion (part 2), multicentre trial done in 12 hospital sites (seven in th

23 The Streamline L trial was a prospective, multicentre trial done in 16 hospitals in England.

24 The Streamline C trial was a prospective, multicentre trial done in 16 hospitals in England.

25 -5,6 was a phase 3b, single-arm, open-label, multicentre trial done in 24 hospitals or clinics in Eur

26 The FAME study was a multicentre trial done in Belgium, Denmark, Germany, the

27 MATCHPOINT was a seamless, phase 1/2, multicentre trial done in eight UK Trials Acceleration P

28 ctive-controlled, open-label, international, multicentre trial, done at 106 sites across nine countri

29 This phase 2, double-blind, multicentre trial enrolled individuals with moderate-to-

30 A multicentre trial evaluated the dose-response and tolera

31 The MRC Multicentre trial for Early Epilepsy and Single Seizures

32 We did a randomised, open-label multicentre trial in 59 hospitals--57 in the UK, one in

33 We did a randomised, double-blinded, multicentre trial in adults (n=586) with diabetes and a

34 2, randomised, parallel-group, double-blind multicentre trial in patients with New York Heart Associ

35 stic factors in this rare disease and assist multicentred trials in the evaluation of different treat

36 derline the suitability of blood NfL in gFTD multicentre trials, including cross-lab reliable stratif

37 iated with poor functional outcomes; a large multicentre trial is currently comparing it against barb

38 adical prostate radiotherapy in the MRC RT01 multicentre trial (ISRCTN47772397, n=224) or in the Conv

39 In two placebo-controlled, double-blind, multicentre trials (M2-124 and M2-125) with identical de

40 was a prospective non-randomised controlled multicentre trial observational study.

41 We did a randomised multicentre trial of 1810 patients with non-ST-elevation

42 Multicentre trials of vitamin D supplementation for prev

43 In this phase 2b, double-blind, multicentre trial, patients (aged 18-75 years) with, or

44 PATCH is a seamless phase 2/3, randomised, multicentre trial programme at 52 study sites in the UK.

45 In this open-label, phase 1, multicentre trial, single subcutaneous injections of rAv

46 ernational, open-label, randomised, phase 3, multicentre trial (TH CR-406/SARC021) at 81 academic or

47 REAL07 was an open-label, multicentre trial that was done in 13 centres in Italy a

48 ng cooperation and collaboration to complete multicentre trials that advance knowledge and patient ca

49 We did a multicentre trial to compare the outcomes of patients tr

50 We undertook a randomised, multicentre trial to compare the safety and efficacy of

51 We undertook a randomised, multicentre trial to compare these treatments in patient

52 We undertook a randomised multicentre trial to compare these two approaches.

53 We did a randomised multicentre trial to resolve this issue.

54 We did a randomised multicentre trial to try to resolve this issue.

55 QUEST-1, a phase 3, randomised, double-blind multicentre trial undertaken in 13 countries (Australia,

56 ho were enrolled in the prospective RenalRIP multicentre trial (validation cohort) and who were rando

57 This open-label randomised controlled multicentre trial was part of a larger study.

58 ernational, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-

59 this pragmatic, randomised, parallel-group, multicentre trial, we recruited adults with symptoms sug

60 For this open-labelled, multicentre trial, we recruited patients aged 18 years o

61 In this UK-based multicentre trial, we used an independent central random

62 andomised, double-blind, placebo-controlled, multicentre trial with an adaptive design was done in 32

63 ion and treatment has improved, high-quality multicentre trials with long-term follow-up are needed.